Meadowhawk Biolabs
Meadowhawk Biolabs: A pre-clinical CRO advancing biotech for drug discovery & development.
Founded
2021Meadowhawk Biolabs: A pre-clinical CRO advancing biotech for drug discovery & development.
Meadowhawk Biolabs, founded in 2021 and headquartered in Marlborough, Massachusetts, is a pre-clinical Contract Research Organization (CRO) dedicated to advancing biotechnology for drug discovery and development. The company's core mission is to provide responsive service and reliable results through its comprehensive biotechnology platform. Meadowhawk Biolabs offers a range of services including bioanalytical, pharmacokinetics, and pharmacological support for both small and large molecules, catering primarily to pharmaceutical and biotech companies engaged in early-stage drug development.
Notable figures associated with Meadowhawk Biolabs include industry experts and seasoned professionals in the fields of bioanalytics and pharmacology. The company has garnered attention for its innovative approach and commitment to quality, which has led to successful collaborations with various biotech firms. Meadowhawk Biolabs' impact is marked by its contribution to accelerating drug discovery processes, thereby enhancing the potential for new therapeutic breakthroughs.
Companies similar to Meadowhawk Biolabs include Boca Biolistics, NJ Bio, MedChem Partners and K2bio.
Meadowhawk Biolabs was founded in 2021.
Meadowhawk Biolabs' headquarters is located in Marlborough, MA, US.
Meadowhawk Biolabs' most recent funding round was for $6M (USD) in March 2023.
As of Mar 17, 2023, Meadowhawk Biolabs has disclosed funding of $6M (USD). Undisclosed round amounts are excluded.
Meadowhawk Biolabs has 35 employees as of Feb 5, 2024.
K2bio
k2-biolabs.com
